BERN - Medicines used outside their official label, and some treatments for rare diseases, are not automatic benefits of basic insurance. A doctor asks. The insurer decides case by case. A Federal Office of Public Health study in 2020 found large gaps between the biggest insurers and did not print their names. After a long court fight, RTS obtained the unredacted tables. The figures were reported on Monday and were still the health story in Tuesday's Swiss roundups.

The approval rates now have names

KPT approved 98 percent of the requests in the study. Assura approved 96 percent. Groupe Mutuel stood at 94 percent. CSS handled the most files and approved 74 percent, a little under the national average of 76 percent. Helsana approved 67 percent. Atupri approved 53 percent. Sanitas, at 45 percent, was at the bottom of the published list.

About 80,000 requests were filed last year for benefits that basic insurance does not cover automatically. For a patient, the practical question is which logo is on the policy card. Two people with the same diagnosis can leave the same clinic with different letters.

What Sanitas and the authors dispute

Sanitas told RTS that clinical trials were probably counted as refusals. If those cases were treated as approvals, the insurer said, its rate would sit near 80 percent. The authors of the study rejected that reading. The gaps are too wide, they said, to be explained by the way the numbers were built. Insurers that apply the same rules still come out with different approval rates.

The insurers' association says a 2024 reform has already dealt with the problem the study described. Comparative figures for the years after that reform have not been published. Atupri was the insurer that answered RTS with newer numbers of its own. It approved 77 percent of 1,060 requests in 2024, and 81 percent of 1,327 requests in 2025. That is a rise at one company. It is not a national table.

A hospital says the gap is still open

Solange Peters, head of oncology at Lausanne University Hospital, told RTS the 2024 reform had not done the job. She described two patients with pancreatic cancer seen this week. Same illness, same medicines, same medical reasons. One insurer agreed to pay. The other refused.

The argument sits on top of a premium bill that is already rising. Comparis and the insurers expect basic premiums to climb by about 5 percent in 2027. A separate study has warned that US pressure on medicine prices could land on Swiss premium payers. Off-label decisions are a smaller line in that budget, and for the person waiting on a letter they are the whole file.